IFNA17 and diabetic macular edema: In some cases, we have used these anti-proliferative and anti-VEGF properties, with an off-label subtenon injection of IFNα in patients with diabetic macular edema[7] and age-related choroidal neovascularization[8] and we have followed them for a period of 4 months reporting good results.